Nitroxoline

Nitroxoline (CAS 4008-48-4) is an antimicrobial compound employed clinically in managing urinary tract infections primarily caused by Gram-negative bacteria. Recent studies suggest additional activities, including against fungi, Mycoplasma, Ureaplasma, and Trichomonas. Its mechanism involves chelation of divalent metal ions (particularly Mg2? and Mn2?), influencing its antibacterial efficacy and bacterial uptake dynamics. Preclinical assays indicate it suppresses serotonin-, agar-, and carrageenan-induced paw edema in rats at an oral dose of 50 mg/kg. Nitroxoline demonstrates bacteriological clearance in pediatric urinary tract infections (200 mg/kg/day, 10 days), without measurable impact on fecal microflora; however, specific IC?? values remain unreported.

References:

[1] Pelletier C,Prognon P,Bourlioux P. Roles of divalent cations and pH in mechanism of action of nitroxoline against Escherichia coli strains. Antimicrob Agents Chemother.1995 Mar;39(3):707-13.

[2] Zaks AS,Zil'ber AL,Kapitonenko TA. Spasmolytic and anti-inflammatory activity of 8-hydroxyquinolines. Farmakol Toksikol.1984 Sep-Oct;47(5):44-7.

[3] Lambert-Zechovsky N,Lévêque B,Bingen E,Pillion G,Chapelle J,Mathieu H. Clinical study and effect of nitroxoline on fecal flora in childrenPathol Biol (Paris).1987 May;35(5):669-72.